Exploring the Role of Amitriptyline in Modulating Gag Reflex Sensitivity

Area of Science:

• Dentistry
• Pharmacology
• Clinical Trials

Background:

• The gag reflex is a crucial airway defense mechanism.
• It significantly impacts dental care accessibility for up to 44% of patients.
• Severe gag reflex can lead to avoidance of necessary dental treatments.

Purpose of the Study:

• To assess the efficacy of topical amitriptyline in mitigating gag reflex intensity.
• To compare amitriptyline's effect against lidocaine, a standard treatment.
• To measure gag reflex reduction using the Gag Trigger Point Index (GTPI).

Main Methods:

• A randomized single-blind clinical trial involving 48 participants with elevated GTPI scores.
• Participants were divided into two groups: amitriptyline gargle (15 mg/mL) and lidocaine spray (10%).
• GTPI was measured post-intervention, alongside patient-reported taste and smell satisfaction.

Main Results:

• Both amitriptyline and lidocaine significantly reduced gag reflex intensity (P < 0.001).
• Amitriptyline group showed a GTPI change from 4.04 to 1.29; lidocaine group from 4.46 to 2.42.
• No significant differences were found between the groups regarding gag reflex reduction or sensory perception.

Conclusions:

• Topical amitriptyline presents a potential alternative to lidocaine for managing the gag reflex.
• It is particularly suitable for patients intolerant to lidocaine.
• Further research is required to establish long-term safety and elucidate pharmacological effects.